Nestor Punay, MD
Neurology · Beaumont, TXNPI 1801870522
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $206,697 of the $233,886 with a category attached, or 88.4%. AbbVie accounts for 90.1% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2021 at $62,223 and has fallen 56.5% since, to $27,096 in 2025. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,397 payments — averaging $167.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$211K
- Acadia Pharmaceuticals Inc$2K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Boston Scientific$1K
- Lundbeck LLC$1K
- plus $15K from 54 others
What the payments were for
- Speaking & faculty fees$206,69788%
- Travel & lodging$2,4941%
- Food & beverage$24,45810%
- Education$2370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$183,010
- QULIPTA$69,256
- NURTEC ODT$1,500
- RNS Neurostimulator Kit$1,060
- VERCISE$957
- Infinity DBS Pulse Generators$245
- Mavenclad$149
How this compares
$233,886 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 37 | $284,895 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 33 | $196,891 |
| UbrelvyUbrogepant | 108 | $170,547 |
| NuplazidPimavanserin Tartrate | 30 | $168,894 |
| RexultiBrexpiprazole | 80 | $121,073 |
| QuliptaAtogepant | 88 | $114,413 |
| AustedoDeutetrabenazine | 13 | $107,981 |
| XcopriCenobamate | 44 | $59,718 |
| AptiomEslicarbazepine Acetate | 30 | $45,079 |
| NuedextaDextromethorphan Hbr/Quinidine | 28 | $44,415 |
| Aimovig AutoinjectorErenumab-Aooe | 27 | $24,890 |
| Memantine Hcl | 1,031 | $22,981 |
| Nurtec OdtRimegepant Sulfate | 11 | $22,678 |
| RytaryCarbidopa/Levodopa | 11 | $22,335 |
| OngentysOpicapone | 12 | $18,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $713 | $303,03649 claims |
| AbbVieUbrelvy, Qulipta, Botox | $210,624 | $298,523207 claims |
| Grifols USA, LLCGamunex-C | $116 | $196,89133 claims |
| Acadia Pharmaceuticals IncNuplazid | $2,049 | $168,89430 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $475 | $121,07380 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,421 | $107,98113 claims |
| SK Life Science, Inc.Xcopri | $690 | $59,71844 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $719 | $45,07930 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $96 | $44,41528 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $827 | $24,06932 claims |
| PfizerNurtec Odt | $1,074 | $22,67811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 neurology providers in Texas.
Other neurology in Beaumont
- Ann BassSan Antonio$1.7M
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Benjamin GreenbergDallas$773K
- Annette OkaiPlano$730K
- Waleed El-FekyDallas$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.